Drug Trial Radar · NCT06963320
Phase II Clinical Study of H001 Capsule in the Prevention of Venous Thromboembolism After Total Knee Arthroplasty
Last checked: Nov 19, 2026Latest source record: May 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
320
Planned (sponsor's estimate)
Start
Jan 20, 2025
Primary completion
Jun 30, 2025
Study completion Jul 30, 2025
Sponsor
- Lead sponsor
- Livzon Pharmaceutical Group Inc.Industry
- Sponsor type
- Industry
- First posted
- May 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, open-label, positive-controlled Phase II clinical study to evaluate the efficacy and safety of H001 capsules in the prevention of venous thromboembolism (VTE) in subjects undergoing Total Knee Arthroplasty.
Conditions
- Circulatory Disease
Interventions
H001 Capsule 200mg-qdDrug
H001 Capsule, 50 mg/capsule, 200 mg orally once daily for 10-14 days.
Enoxaparin Sodium InjectionDrug
Enoxaparin Sodium Injection,0.4 mL: 4000 AXaIU, 40 mg subcutaneously once daily for 10-14 days
H001 Capsule 300mg-qdDrug
H001 Capsule, 50 mg/capsule, 300 mg orally once daily for 10-14 days.
H001 Capsule 200mg-bidDrug
H001 Capsule, 50 mg/capsule, 200 mg orally twice daily for 10-14 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of total VTETime frame: Within 14 days post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Sixth People's Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.